Navigation Links
Radius Raises Additional $15 Million, Increasing Second Private Equity Financing Round to $82.5 Million
Date:11/20/2008

CAMBRIDGE, Mass., Nov. 20 /PRNewswire/ -- Radius Health ("Radius") announced today that it has raised an additional $15 million to its second institutional financing round, increasing total Series C investment to $82.5 million and the total amount raised since the company's inception to $106.5 million. All existing institutional investors participated in the financing, led by MPM Bio IV NVS Strategic Fund and including MPM Capital, The Wellcome Trust, HealthCare Ventures, Oxford Bioscience Partners, BB Biotech Ventures, and Scottish Widows Investment Partnership.

Radius will use the additional funding, along with existing cash resources, to support the continued advancement of the company's clinical and preclinical development programs. Radius anticipates results from its Phase II clinical trial of BA058, a bone anabolic therapy for the treatment of osteoporosis, in the first quarter of 2009. Earlier this year, the company initiated a Phase I clinical trial of RAD1901, a novel SERM (selective estrogen receptor modulator) for the treatment of hot flashes, on which Radius expects to commence a Phase IIa study in the first quarter of 2009. In addition, the company recently announced selection of the first preclinical candidate from its SARM (selective androgen receptor modulator) discovery program for treatment of muscle loss, with an investigational new drug (IND) filing expected in the second quarter of 2009.

"We are extremely pleased with the strong continuing confidence of our investors in Radius' progress," said C. Richard Lyttle, PhD, President and CEO of Radius. "We are finishing 2008 in a strong position, with a broad and maturing portfolio of drug candidates for osteoporosis and women's health, an option agreement with a major pharmaceutical company to license BA058 for late-stage development, and significant cash resources at our disposal."

About Radius (www.radiuspharm.com)

Radius is a leading company in the discovery and development of a new generation of drug therapies for osteoporosis and women's health. Radius has raised $106.5 million in private equity financing since its establishment in 2003 and is based in Cambridge, Massachusetts.

    Contact:
    Nick Harvey
    Chief Financial Officer
    1-617-551-4704


'/>"/>
SOURCE Radius Health
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Radius Selects First Preclinical Candidate From SARM Discovery Program for the Treatment of Muscle Loss and Other Musculoskeletal Conditions
2. Radius Completes Enrollment of Phase II Clinical Trial of BA058 for Osteoporosis
3. Ironwood Raises $50 Million to Advance Linaclotide Through Phase 3
4. ESBATech Raises Additional CHF 23M (USD 22M), Extending Series B Venture Financing
5. Celator Pharmaceuticals Raises Series C Financing in Excess of $22.5 Million
6. Light Sciences Oncology Raises $40.1 Million in Series C Financing
7. Romark Laboratories Raises $18 Million in Institutional Financing
8. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
9. EntreMed Raises $20 Million to Support Clinical Development Program
10. Globus Medical Raises $110 Million in Series E Financing Round
11. AMT Intends to Incorporate Additional Data to its Marketing Authorization Dossier for Glybera(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... April 27, 2016 ... the  "Global Anesthesia Disposables Market 2016-2020"  report ... ) ,The global anesthesia disposables market ... of 4.03% during the period 2016-2020.  ... threat to patients, safety. Organizations like the ...
(Date:4/27/2016)... April 27, 2016 Global  ... 2.14 billion by 2022, according to a new ...      (Logo: http://photos.prnewswire.com/prnh/20150105/723757 ) , ... the efficiency and accuracy delivered by the new ... for novel urinalysis instruments and consumables. For instance, ...
(Date:4/27/2016)... 2016 At the Sachs CEO ... a Phase 2 clinical study of its lead drug ... cochlear implantation (CI) surgery. This large, placebo-controlled, double-blind, phase ... Germany and France . ... the time of surgery. "Despite advances in cochlear implant ...
Breaking Medicine Technology:
(Date:4/28/2016)... Thousand Oaks, CA (PRWEB) , ... April 28, 2016 , ... ... brand is currently number one in Central America and is looking to grow their ... provide marketing for such an exceptional brand as La Sirena Foods and ...
(Date:4/28/2016)... ... April 28, 2016 , ... Head Over Heels Athletic Arts’ gymnast, ... The competition will be held at the University of Montana on April 28-May 1. ... the Mississippi River. , In order to qualify, Varize needed to place top seven ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... open availability of a new CDISC standard, Clinical Trial Registry (CTR) XML. ... This innovative standard will make it possible to build applications that generate ...
(Date:4/28/2016)... ... April 28, 2016 , ... Cosmetic Town, an online plastic surgery ... The forum section was recently revamped and upgraded to allow even more interaction between ... across the country. , According to the senior editor of Cosmetic Town, “We are ...
(Date:4/28/2016)... Beach, FL (PRWEB) , ... April 28, 2016 , ... ... the spring season. Smart pots are frequently used by professional organic farmers and nurseries ... growers to order their supply of fabric pots. Our goal is to offer wholesale ...
Breaking Medicine News(10 mins):